For example, the silencing Nrf2 can increase the sensitivity of cisplatin-resistant ovarian cancer cell strain to cisplatin and that of lung cancer cells to doxorubicin [36, 37]. This evidence concerns the gene NFE2L2 and ovarian carcinoma.